NIH Director Collins Stays On: Continuity For ‘Moonshot’ – And Barrier To ‘March In’
For industry, the sole health agency head held over from the Obama Administration means the ‘Moonshot’ priorities will move forward – and one possible threat to pricing is cut off.
You may also be interested in...
Selling government efficiency as a campaign issue has not been an easy task for Democrats. COVID-19 – and especially support for international responses – may present a new opportunity.
Norman Sharpless, director of the National Cancer Institute, will become acting FDA commissioner when Scott Gottlieb departs.
Pharma In The Crosshairs: Dual Drug Pricing Hearings Portend Rocky Road Ahead – And Potential Subpoenas
Last week’s US House and Senate hearings on drug pricing underscore how quickly the negative attention has turned to industry. With more public discussions planned – including potential testimony from pharma execs – here’s what can be expected in the months ahead.